CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Kinnov-Therapeutics is developing KT-110, a novel drug aimed at helping individuals with alcohol use disorders regain control over their consumption. This innovative treatment targets a newly discovered pathway involved in addiction, promising significant reductions in alcohol intake and improved recovery rates.
Alcohol use disorders (AUD) is a disease characterised by uncontrolled alcohol consumption. 283 million persons worldwide suffer from alcohol mise use which cause more than 3 million dead and 132.6 million disability-adjusted life years.
Alcoholism has also huge damaging effects on families, communities and the overall society.
Current drug therapies against AUD are unsuccessful due to poor efficacy and strong side effects.
That situation leads to low patient recovery and only 10% of AUD people…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
